Your browser doesn't support javascript.
loading
Can we reduce the cost of illness with more compliant patients? An estimation of the effect of 100% compliance with hypertension treatment.
Koçkaya, Güvenç; Wertheimer, Albert.
Afiliação
  • Koçkaya G; Pharmacology & Clinical Pharmacology, Istanbul University, Istanbul, Turkey. guvenckockaya@yahoo.com
J Pharm Pract ; 24(3): 345-50, 2011 Jun.
Article em En | MEDLINE | ID: mdl-21676859
ABSTRACT

INTRODUCTION:

The current study was designed to calculate the direct cost of noncompliance of hypertensive patients to the US health system. Understanding these expenses can inform screening and education budget policy regarding expenditure levels that can be calculated to be cost-beneficial.

METHOD:

The study was conducted in 3 parts. First, a computer search of National Institutes of Health Web sites and professional society Web sites for organizations with members that treat hypertension, and a PubMed search were performed to obtain the numbers required for calculations. Second, formulas were developed to estimate the risk of noncompliance and undiagnosed hypertension. Third, risk calculations were performed using the information obtained in part 1 and the formulas developed in part 2.

RESULTS:

Direct risk reduction for stroke caused by hypertension, heart attack, kidney disease, and heart disease was calculated for a 100% compliant strategy. Risk, case, and cost reduction for a 100% compliant strategy for hypertension were 32%, 8.5 million and US$ 72 billion, respectively.

DISCUSSION:

Our analysis means that the society can spend up to the cost of noncompliance in screening, education, and prevention efforts in an attempt to reduce these costly and traumatic sequelae of poorly controlled hypertension in the light of published analysis.
Assuntos

Texto completo: 1 Temas: ECOS / Aspectos_gerais / Financiamentos_gastos Bases de dados: MEDLINE Assunto principal: Cooperação do Paciente / Efeitos Psicossociais da Doença / Hipertensão Tipo de estudo: Health_economic_evaluation Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: America do norte Idioma: En Revista: J Pharm Pract Assunto da revista: FARMACIA Ano de publicação: 2011 Tipo de documento: Article País de afiliação: Turquia

Texto completo: 1 Temas: ECOS / Aspectos_gerais / Financiamentos_gastos Bases de dados: MEDLINE Assunto principal: Cooperação do Paciente / Efeitos Psicossociais da Doença / Hipertensão Tipo de estudo: Health_economic_evaluation Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: America do norte Idioma: En Revista: J Pharm Pract Assunto da revista: FARMACIA Ano de publicação: 2011 Tipo de documento: Article País de afiliação: Turquia